Table 1.
Comparison of distribution of age, number of positive nodes, treatment, tumor size, grade, and surgery type between ER-positive patients included in the present study and those who were excluded
| Included ER+ patients
(n = 1065) |
Not included ER+ patients
(n = 999) |
||||
|---|---|---|---|---|---|
| Variable | No. (%) | No. (%) | P* | ||
| Age, y | .53 | ||||
| <50 | 511 (48.0) | 466 (46.7) | |||
| ≥50 | 553 (52.0) | 533 (53.3) | |||
| Tumor size, cm | <.001 | ||||
| ≤2.0 | 481 (45.4) | 566 (57.4) | |||
| 2.1-4.0 | 465 (43.9) | 319 (32.3) | |||
| ≥4.1 | 114 (10.7) | 102 (10.3) | |||
| Positive lymph nodes | .17 | ||||
| 1–3 | 722 (67.8) | 708 (71.2) | |||
| 4-9 | 300 (28.2) | 244 (24.5) | |||
| ≥10 | 43 (4.0) | 43 (4.3) | |||
| Tumor grade | .004 | ||||
| Well | 120 (11.3) | 152 (15.2) | |||
| Moderate | 499 (46.9) | 456 (45.7) | |||
| Poor | 405 (38.0) | 318 (31.8) | |||
| Unknown | 41 (3.8) | 73 (7.3) | |||
| Treatment | .16 | ||||
| AC | 519 (48.7) | 518 (51.8) | |||
| AC-P | 546 (51.3) | 481 (48.2) | |||
| Surgery type | .007 | ||||
| Lumpectomy | 461 (43.3) | 492 (49.3) | |||
| Mastectomy | 604 (56.7) | 507 (50.7) | |||
*
All statistical tests were chi-square distributed. All P values were one-sided. AC = doxorubicin/cyclophosphamide; ER = estrogen receptor; P = paclitaxel.